Skip to content
Buy This GLP
← Research
Evidence

Why Do People Turn Down a GLP-1 Prescription? What One Study Found

In a supervised weight program, 57 of 78 people offered liraglutide declined. The researchers reported out-of-pocket cost as the main reason.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
78 people were offered the drug21 started it57 declined — mainly the out-of-pocket costAverage loss: 3.2% among starters, 1.4% among decliners.Six-week follow-up in a supervised weight program.

When you use the GLP-1 cost guide to compare quotes, check what you would owe after coverage and what the same prescription would cost at renewal. In one supervised weight program, out-of-pocket cost was the main reason people declined liraglutide [1]. The study did not establish a refusal rate across all GLP-1 prescriptions.

Who was offered liraglutide

The 12-week program enrolled 174 adults with obesity. At week six, the researchers offered liraglutide to the 78 participants who had lost less than 2.5% of their starting weight. Twenty-one agreed to start and 57 declined.

Over the next six weeks, those who started lost an average of 3.5 kg (3.2%), compared with 1.3 kg (1.4%) among those who declined (P<0.001). Four participants reported nausea and two reported upper abdominal pain.

What national data say about access

A separate analysis of U.S. Medical Expenditure Panel Survey data from 2017 to 2023 measured use of GLP-1 receptor agonists and SGLT2 inhibitors together [2]. If coverage is uncertain, the insurance worksheet helps you check the formulary and record any approval requirements. The survey measured medication use across both drug classes and cannot tell you how often people turned down a GLP-1 prescription.

What Swedish doctors reported

A 2024 survey in five Swedish regions received 190 responses, a response rate of 28%, and analyzed 163 [3]. During that survey, 86% identified supply shortages and 69% identified high patient copayments as prescribing barriers. The figures describe the responding doctors during that period.

Starting and staying on treatment

The research on why people stop taking a GLP-1 examines patients who had already begun treatment. The liraglutide study captured an earlier decision, when participants were first offered the prescription.

Frequently asked

Why did people decline liraglutide in the study?
Out-of-pocket cost was the main reason the researchers reported. In the supervised program, 57 of 78 people offered liraglutide declined.
How did weight change among people who started?
Those who started lost an average of 3.2% over the next six weeks, compared with 1.4% among those who declined. Participants chose whether to start, so the study cannot establish how much of the difference was due to medication.
Does that refusal rate apply to other GLP-1 prescriptions?
The rate comes from one program that offered liraglutide to people who had lost less than 2.5% of their starting weight by week six. It cannot establish how many patients decline other prescriptions.

Sources

  1. [1] Gilardini L, et al. (2026). Effectiveness of Liraglutide in Patients With Obesity Who Are Early Non-Responders to Lifestyle Intervention: A Real-World Study Journal of Obesity. PMID 42658045
  2. [2] Jacobs M, Fang Q, Ellis C (2026). Trends in GLP-1 Receptor Agonist and SGLT2-Inhibitor Utilization and Expenditure Between 2017-2023: Demographic, Income, and Insurance Associations Journal of General Internal Medicine. PMID 41984414
  3. [3] Sundell I, Wettermark B, Sundström A, Martinell M, Ericsson B (2026). Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey BMC Primary Care. PMID 42557543

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence